IN2015DN04175A - - Google Patents

Info

Publication number
IN2015DN04175A
IN2015DN04175A IN4175DEN2015A IN2015DN04175A IN 2015DN04175 A IN2015DN04175 A IN 2015DN04175A IN 4175DEN2015 A IN4175DEN2015 A IN 4175DEN2015A IN 2015DN04175 A IN2015DN04175 A IN 2015DN04175A
Authority
IN
India
Prior art keywords
combination
inhibiting
decreasing
treating
methods
Prior art date
Application number
Inventor
Qing Sheng
hui qin Wang
Fang Li
Jinsheng Liang
Zhu Alexander Cao
John Monahan
Richard Versace
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN04175A publication Critical patent/IN2015DN04175A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical combination comprising (a) a compound of formula (I) [Chemical formula should be inserted here as it appears on Abstract in paper form] or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading targeting decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering from a proliferative disease; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
IN4175DEN2015 2012-11-07 2013-11-06 IN2015DN04175A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723474P 2012-11-07 2012-11-07
US201361790796P 2013-03-15 2013-03-15
PCT/US2013/068691 WO2014074580A1 (en) 2012-11-07 2013-11-06 Combination therapy

Publications (1)

Publication Number Publication Date
IN2015DN04175A true IN2015DN04175A (en) 2015-10-16

Family

ID=49681127

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4175DEN2015 IN2015DN04175A (en) 2012-11-07 2013-11-06

Country Status (12)

Country Link
US (3) US20150290204A1 (en)
EP (1) EP2916841A1 (en)
JP (1) JP2015536986A (en)
KR (1) KR20150081344A (en)
CN (1) CN105120868A (en)
AU (2) AU2013341271A1 (en)
BR (1) BR112015010396A2 (en)
CA (1) CA2890699A1 (en)
IN (1) IN2015DN04175A (en)
MX (1) MX2015005798A (en)
RU (1) RU2015121424A (en)
WO (1) WO2014074580A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
AU2014372166B2 (en) * 2013-12-23 2017-10-26 Novartis Ag Pharmaceutical combinations
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
CN107801397B (en) * 2015-02-13 2021-07-30 达纳－法伯癌症研究所公司 LRRK2 inhibitors and methods of making and using the same
US11058977B2 (en) 2018-07-23 2021-07-13 Caterpillar Inc. 3D printed staged filtration media packs
US10981335B2 (en) 2019-02-06 2021-04-20 Caterpillar Inc. Filtration media packs produced using additive manufacturing
CA3145864A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
GB201915618D0 (en) * 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (en) 2021-02-25 2023-07-05 Incyte Corp SPIROCYCLIC LACTAMS AS JAK2 INHIBITORS V617F
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
CN116284001A (en) * 2023-01-30 2023-06-23 中国药科大学 DCLK1 inhibitor, preparation method, pharmaceutical composition and application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
DK1611112T3 (en) 2003-02-11 2012-11-19 Cancer Res Inst ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS
JO2783B1 (en) 2005-09-30 2014-03-15 نوفارتيس ايه جي 2-Amino-7,8-Dihidro-6H-Pyrido(4,3-D)Pyrimidin-5-ones
MX2009006081A (en) * 2006-12-08 2009-06-17 Irmc Llc Compounds and compositions as protein kinase inhibitors.
CA2763633A1 (en) * 2009-05-27 2010-12-02 Gary T. Wang Pyrimidine inhibitors of kinase activity
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20130137709A1 (en) * 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
ME02200B (en) * 2011-02-02 2016-02-20 Novartis Ag Methods of using alk inhibitors
AU2012280931A1 (en) * 2011-07-07 2014-02-27 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds

Also Published As

Publication number Publication date
MX2015005798A (en) 2015-09-23
EP2916841A1 (en) 2015-09-16
US20150290204A1 (en) 2015-10-15
US20160287605A1 (en) 2016-10-06
US20170157134A1 (en) 2017-06-08
RU2015121424A (en) 2016-12-27
JP2015536986A (en) 2015-12-24
CA2890699A1 (en) 2014-05-15
WO2014074580A1 (en) 2014-05-15
CN105120868A (en) 2015-12-02
KR20150081344A (en) 2015-07-13
BR112015010396A2 (en) 2017-07-11
AU2017200232A1 (en) 2017-02-02
AU2013341271A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
IN2015DN04175A (en)
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
JO3776B1 (en) PHARMACEUTICAL COMBINATIONS of a CDK4/6 inhibitor and B-Raf inhibitor
EA201290859A1 (en) TREATMENT OF LUPUS-ARTHRITIS USING LAQUINIMODE
WO2015097621A3 (en) Pharmaceutical combinations
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2014002171A (en) Combination treatments for hepatitis c.
MX2014002459A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
MX337614B (en) Treatment of lupus nephritis using laquinimod.
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX369385B (en) Products for healing of tissue wounds.
TN2013000414A1 (en) 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX2012014521A (en) Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation.
MX2010002735A (en) Titration package for neramexane and its use in the treatment of an inner ear disorder.
WO2012064897A3 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
IN2014DN05869A (en)
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
MX2012013879A (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases.
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor